Skip to main content
. 2017 Oct 9;69(11):1714–1723. doi: 10.1002/acr.23165

Table 2.

Mean comorbidities, no. medications, and scores for depression, anxiety, and quality of life by dryness sensitivity classification. Proportions of patients in the different groups with specific comorbidities and receiving particular treatmentsa

Ocular sensitivity Oral sensitivity
Stoical (n = 351) Accurate (n = 130) Sensitive (n = 200) Comparison P Stoical (n = 444) Accurate (n = 179) Sensitive (n = 58) Comparison P
No. comorbidities 3.4 ± 2.3 3.9 ± 2.5 3.8 ± 2.6 F2,678 = 2.90 0.056 3.4 ± 2.3 3.8 ± 2.6 3.9 ± 2.7 F2,678 = 9.5 0.078
No. medications 5.5 ± 4.1 5.7 ± 3.7 6.3 ± 4.2 F2,678 = 2.52 0.081 5.4 ± 3.9b 6.6 ± 4.5c 5.8 ± 3.9d F2,678 = 4.97e 0.007e
Anxiety (HADS) 7.3 ± 4.5b 8.4 ± 4.8c 8.9 ± 4.4c F2,661 = 8.75e < 0.001e 7.3 ± 4.4b 9.0 ± 4.8c 10.2 ± 4.0c F2,661 = 16.45e < 0.001e
Depression (HADS) 5.3 ± 3.7b 6.4 ± 4.3c 6.9 ± 4.3c F2,661 = 11.23e < 0.001e 5.2 ± 3.6b 7.2 ± 4.4c 8.1 ± 4.3c F2,661 = 24.00e < 0.001e
Quality of life (VAS) 63.8 ± 20.6b 56.6 ± 22.5c 56.3 ± 21.2c F2,659 = 10.09e < 0.001e 63.4 ± 20.2b 54.3 ± 22.5c 53.9 ± 22.7c F2,659 = 14.14e < 0.001e
Specific comorbidities
Fibromyalgia 6.3c 8.5d 14.0b Χ2(2) = 9.39e 0.009e 7.0c 11.2d 17.2b Χ2(2) = 8.08e 0.018e
IBS 5.4c 7.7d 12.0b Χ2(2) = 7.70e 0.021e 7.7c 5.0c 17.2b Χ2(2) = 9.13e 0.010e
Mental illness 3.1 6.2 4.0 Χ2(2) = 2.27 0.321 2.7 6.7 5.2 Χ2(2) = 5.61 0.061
Treatments, %
Xerogenic medication use 37.3b 46.2d 50.0c Χ2(2) = 9.14e 0.010e 39.2 48.6 51.7 Χ2(2) = 6.72e 0.035e
Symptomatic treatment for dryness 97.7 96.9 97.5 Χ2(2) = 0.25 0.883 97.1 97.8 100.0 Χ2(2) = 1.875 0.392
Pilocarpine 7.1 9.2 7.5 Χ2(2) = 0.61 0.739 7.2 10.1 3.4 Χ2(2) = 3.04 0.218
Saliva substitute 40.1b 56.4c 43.1d Χ2(2) = 13.83e 0.001e
Lachrymal substitute 82.6c 83.1c 71.5b Χ2(2) = 10.95e 0.004e
Punctal plugging or cauterization 18.8b 33.8c 22.0d Χ2(2) = 12.33e 0.002e
a

Values are the mean ± SD unless otherwise indicated. HADS = Hospital Anxiety and Depression Scale; VAS = visual analog scale; IBS = irritable bowel syndrome.

b

Significantly different from groups ‡ and § in post hoc tests (P < 0.05 for continuous measures, P < 0.017 for categorical measures).

c

Significantly different from groups † and § in post hoc tests (P < 0.05 for continuous measures, P < 0.017 for categorical measures).

d

Significantly different from groups † and ‡ in post hoc tests (P < 0.05 for continuous measures, P < 0.017 for categorical measures).

e

Statistically significant.